# 7. Adverse Effects Profile

[← Previous: Drug Interactions](06-drug-interactions.md) | [Back to Main](../README.md) | [Next: Dosing Guidelines →](08-dosing-guidelines.md)

---

## 7.1 Common Adverse Effects by ASM

| ASM | Common Effects | Serious/Rare Effects | Monitoring |
|-----|----------------|----------------------|------------|
| **Levetiracetam** | Somnolence, irritability, behavioral changes | Psychosis (rare) | Mood/behavior |
| **Lamotrigine** | Rash, headache, dizziness | SJS/TEN (slow titration reduces risk) | Rash (first 8 weeks) |
| **Valproate** | Weight gain, tremor, hair loss, GI upset | Hepatotoxicity, pancreatitis, teratogenicity | LFTs, ammonia, CBC |
| **Carbamazepine** | Dizziness, diplopia, ataxia, hyponatremia | SJS/TEN (HLA-B*1502), aplastic anemia | HLA-B*1502 (Asian), CBC, Na |
| **Oxcarbazepine** | Hyponatremia, dizziness, fatigue | SJS/TEN | Sodium levels |
| **Phenytoin** | Gingival hyperplasia, hirsutism, ataxia | SJS/TEN, osteoporosis, cerebellar atrophy | Drug level, vitamin D |
| **Phenobarbital** | Sedation, cognitive impairment | Dependence, paradoxical hyperactivity (children) | Drug level |
| **Topiramate** | Cognitive slowing, paresthesias, weight loss | Kidney stones, metabolic acidosis, glaucoma | Bicarbonate, renal function |
| **Zonisamide** | Drowsiness, anorexia, cognitive effects | Kidney stones, oligohidrosis (children) | Renal function |
| **Gabapentin** | Sedation, weight gain, peripheral edema | None significant | - |
| **Pregabalin** | Sedation, weight gain, peripheral edema | None significant | - |
| **Lacosamide** | Dizziness, diplopia, nausea | PR prolongation | ECG (baseline, titration) |
| **Perampanel** | Dizziness, somnolence, aggression | Psychiatric effects | Mood/behavior |
| **Brivaracetam** | Somnolence, dizziness | Psychiatric effects (less than LEV) | Mood/behavior |
| **Clobazam** | Sedation, drooling | Tolerance, dependence | - |
| **Felbamate** | Insomnia, weight loss, headache | Aplastic anemia, hepatic failure | CBC, LFTs (frequent) |
| **Vigabatrin** | Fatigue, weight gain | Visual field defects (irreversible) | Visual fields every 3 months |

---

## 7.2 Idiosyncratic Reactions Requiring Genetic Testing

| ASM | HLA Allele | Population | Reaction |
|-----|------------|------------|----------|
| **Carbamazepine** | HLA-B*15:02 | Han Chinese, Thai, Malaysian, Filipino, Indian | SJS/TEN |
| **Oxcarbazepine** | HLA-B*15:02 | Same as above | SJS/TEN |
| **Phenytoin** | HLA-B*15:02 | Same as above | SJS/TEN |
| **Carbamazepine** | HLA-A*31:01 | European, Japanese | DRESS, SJS/TEN, MPE |
| **Lamotrigine** | HLA-B*15:02 | Han Chinese (weaker association) | SJS/TEN |

> **Recommendation:** HLA-B*15:02 testing before carbamazepine/oxcarbazepine/phenytoin in at-risk populations.

---

## 7.3 Weight Effects

| Weight Gain | Weight Neutral | Weight Loss |
|-------------|----------------|-------------|
| Valproate | Lamotrigine | Topiramate |
| Carbamazepine | Levetiracetam | Zonisamide |
| Gabapentin | Lacosamide | Felbamate |
| Pregabalin | Oxcarbazepine | |
| Vigabatrin | Phenytoin | |
| | Brivaracetam | |

---

## 7.4 Cognitive Effects

| Minimal Cognitive Effects | Moderate Effects | Significant Effects |
|---------------------------|------------------|---------------------|
| Lamotrigine | Carbamazepine | Topiramate |
| Levetiracetam | Valproate | Phenobarbital |
| Gabapentin | Oxcarbazepine | Phenytoin (chronic) |
| Lacosamide | | Benzodiazepines |
| Brivaracetam | | |

---

## 7.5 Psychiatric Effects

### Risk of Behavioral/Psychiatric Adverse Effects

| Higher Risk | Lower Risk |
|-------------|------------|
| Levetiracetam | Lamotrigine (may improve mood) |
| Topiramate | Gabapentin (may reduce anxiety) |
| Perampanel | Pregabalin (may reduce anxiety) |
| Phenobarbital | Carbamazepine (mood stabilizer) |
| Zonisamide | Valproate (mood stabilizer) |

### FDA Suicidality Warning

> ⚠️ All ASMs carry increased risk of suicidal thoughts/behavior (OR 1.8)
> - Highest risk in first 6 months
> - Monitor all patients closely
> - Counsel patients and families

---

## 7.6 Bone Health Effects

| Increased Osteoporosis Risk | Considerations |
|----------------------------|----------------|
| Phenytoin | Monitor vitamin D, bone density |
| Phenobarbital | Supplement calcium + vitamin D |
| Carbamazepine | Consider bisphosphonates if indicated |
| Valproate | |
| Oxcarbazepine | |

### Bone Health Monitoring

```
For patients on enzyme-inducing ASMs:
├── Baseline vitamin D level
├── Annual vitamin D monitoring
├── DEXA scan if risk factors present
├── Calcium 1000-1200 mg/day
└── Vitamin D 800-2000 IU/day
```

---

## 7.7 Dermatologic Reactions

### Rash Risk by ASM

| High Risk | Moderate Risk | Low Risk |
|-----------|---------------|----------|
| Lamotrigine* | Carbamazepine | Levetiracetam |
| Phenytoin | Oxcarbazepine | Gabapentin |
| | Phenobarbital | Pregabalin |
| | | Valproate |

*Slow titration significantly reduces risk

### Serious Cutaneous Adverse Reactions (SCARs)

| Reaction | Features | Onset |
|----------|----------|-------|
| **SJS** (Stevens-Johnson Syndrome) | Mucosal involvement, <10% BSA | 1-8 weeks |
| **TEN** (Toxic Epidermal Necrolysis) | >30% BSA detachment | 1-8 weeks |
| **DRESS** | Rash, eosinophilia, organ involvement | 2-8 weeks |

### Red Flags Requiring Immediate Discontinuation

- Mucosal involvement (mouth, eyes, genitals)
- Systemic symptoms (fever, lymphadenopathy)
- Facial edema
- Skin pain out of proportion to appearance
- Blistering or skin detachment

---

## 7.8 Hyponatremia Risk

| High Risk | Moderate Risk | Low Risk |
|-----------|---------------|----------|
| Oxcarbazepine | Carbamazepine | All others |
| Eslicarbazepine | | |

### Risk Factors for Hyponatremia

- Age >65
- Concurrent diuretics
- High ASM dose
- Female sex
- Low baseline sodium

### Management

```
Na 130-134 mEq/L → Monitor closely
Na 125-129 mEq/L → Consider dose reduction or switch
Na <125 mEq/L → Discontinue and switch ASM
```

---

[← Previous: Drug Interactions](06-drug-interactions.md) | [Back to Main](../README.md) | [Next: Dosing Guidelines →](08-dosing-guidelines.md)
